Targeted Cancer Therapy and Mechanisms of Resistance

• Beste egile batzuk: De Falco, Valentina (Argitaratzailea)
• Formatua: Baliabide elektronikoa Liburu kapitulua
• Hizkuntza: ingelesa
• Argitaratua: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
• Gaiak: Research & information: general; Biology, life sciences; 3D spheroids; photothermy; gold nanoparticles; doxorubicin resistance; colorectal cancer; cellular prion protein; PrPC; PRNP; cancer; cancer stem cell; targeted cancer therapy; brain metastases; treatment; non-small cell lung carcinoma; EGFR; ALK; immunotherapy; HDAC6; bortezomib-resistance; HDAC6-selective inhibitor; bortezomib; carfilzomib; multiple myeloma; LMP2; combination therapy; colorectal cancer cells; drug resistance; 5-Fluorouracil; thymidylate synthase; exome sequencing; CD47; immune activation; pro-tumoral macrophages; breast cancer; polo-like kinase 1 (PLK1); pyrazole; quantitative structure-activity relationship; hybridization; ovarian cancer; cisplatin; cisplatin resistance; PARPi; niraparib; Twist; lethality; AF4; cell culture; FGFR2; HOXA9; MLL-AF4; nucleus; target therapy; t(4; 11) leukemia; radiation-resistant; cell death; ERK; EMT; cancer stem cells (CSCs); PD98059; PARP inhibitors; PARP inhibitor resistance; signal transduction networks; pathways; event-free survival; biomarkers; WNT pathway; targeted therapy; Wee1 kinase; cell cycle; tumor resistance; lenvatinib; sorafenib-resistant; hepatocellular carcinoma; FGFR4; autophagy; microRNA
• Sarrera elektronikoa: DOAB: download the publication; DOAB: description of the publication

Tumor cells commonly exhibit dependence on a single activated oncogenic pathway or protein to maintain their malignant proliferation and survival, a phenomenon called "oncogene addiction". According to this concept, protein kinases have been identified as promising molecular targets for ca...